Study of Dalbavancin as Long-Term Suppressive Therapy for Adults with Acute or Chronic Infections

What this Trial Is About

Dalbavancin DAL is an antibiotic that belongs to the lipoglycopeptide family, designed to fight certain Gram-positive bacterial infections. It has a long half-life and can penetrate tissues like skin, bones, joints, lungs, and the peritoneal space. This research evaluates the effectiveness and safety of DAL when used as suppressive therapy to manage acute or chronic infections that have not been successfully treated with previous antibiotics or surgeries. The study looks at adults aged 18 and older who received DAL as suppressive antibiotic therapy between July 2019 and December 2024. This observational study gathers information about patient demographics, medical history, and antibiotic treatment to assess how well DAL controls long-standing infections. Participants who received DAL for other purposes or who were under 18 years old are not included. During the study, researchers will monitor the stability of infections over one year, using the date of the last visit for patients lost to follow-up or followed less than a year. Data collected include infection status, patient characteristics, and treatment details. The study aims to understand DALs ability to maintain infection control and its safety in this patient group, supported by ongoing medical management and follow-up observations.

Efficacy and Safety of Dalbavancin As Suppressive Therapy